Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Wound Care Biologics market size was estimated at USD 1.9 billion in 2022 and is expected to surpass around USD 4.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 10.2% during the forecast period 2022 to 2030.

COVID-19 Impact

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The increased pressure due to the growing rate of hospitalization of COVID-19 patients led to the re-profiling of many hospitals and departments for treating patients with COVID-19. Consequently, many elective surgeries were canceled or postponed worldwide to reserve or redirect the available limited capacities and resources (like hospital beds and patient care professionals) toward COVID-19 patient care.

According to a study published in Advances in Wound Care, by June 2020, 80% of healthcare service providers wearing PPE kits during COVID-19 service duties reportedly had multiple types of skin injuries, such as device-related pressure injuries, moisture-associated skin damage, and skin tears ranging from partial to full-thickness. These injuries can lead to partial or complete loss of skin flaps in extreme cases and chronic wounds. Such wounds are mainly caused in areas like the nose bridge, cheeks, ears, forehead, armpits, groin, and extremities. Among the total cases of such skin injuries, 70.2% of cases were device-related pressure injuries, 26.2% were moisture-associated skin damage, and 6.7% were partial or full-thickness skin tears. To treat such injuries, doctors and nurses (using grade 2 and 3 PPE kits) used wound care biologic products to promote faster wound healing. Such cases across the globe are expected to drive the growth of the wound care biologics products market during the COVID-19 pandemic and the forecast period.

Report Scope of the Wound Care Biologics Market

Wound Care Biologics Market Dynamics

How does the growing prevalence of diseases & conditions affect the wound healing capabilities?

Physical health conditions, such as chronic wounds and surgical wounds, have a negative effect on wound healing. The prevalence of chronic and surgical wounds has increased significantly over the past decade, primarily due to the growing global geriatric population, the rising number of traumatic wounds, the increasing number of surgeries, and the increasing prevalence of conditions like diabetes. Diabetes can increase the overall incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and chronic wounds, which require treatments and incur exorbitant medical expenses. Clearly, the healing of ulcerations in a timely manner is of central importance in any plan for amputation prevention and limb preservation. Wound care biologic products such as bioengineered dermal substitutes promote the healing of chronic ulcerations via two principal modes of action. Firstly, it provides living, human dermal fibroblasts that deposit matrix proteins and facilitate angiogenesis. It also provides a preformed collagen matrix, receptors, and bound growth factors that facilitate the migration and colonization of the host’s epithelial cells, promoting wound closure. Such advantages offered by wound care biologic products will stimulate their demand for faster healing of wounds.

What is the role of 3D printers in the wound care biologics market?

The use of 3D printers has grown extensively in different tissue engineering applications. More recently, specialized printers, also called skin printers, have been introduced to create skin substitutes. A key example is a printer developed by a team from the University of Toronto (Canada) and the Ross Tilley Burn Center at Sunnybrook Hospital (Canada). Further R&D on skin printing will significantly impact the market due to current limitations that do not allow more than two types of cell lines to be incorporated into skin substitutes (largely attributed to the current lack of technology). This will also be a significant benefit for burn victims, who have so far had only limited options for repairing disfigured skin, such as skin grafts (which are painful and aesthetically unappealing) and hydrotherapy solutions (which provide limited results).

Why is the high cost of wound care biologic products a critical restraining factor that is holding back growth of market?

The high cost of chronic wound therapies and wound care biologics may negatively affect their adoption, especially in cost-sensitive markets such as Asia and the RoW. In the case of DFUs—a key application for wound care biologics—this further drives up overall healthcare expenditures, as DFUs are highly prevalent among the 23.9 million Americans with diabetes; they affect as many as 6% of its population. Although many bioengineered products are available in these markets, physicians and patients tend to opt for traditional and basic wound care products due to their low costs. Owing to this significant cost difference, physicians and patients are reluctant to adopt technologically advanced products, which, in turn, is likely to hinder the growth of the market.

In 2021, biological skin substitutes segment accounted for the largest share of the wound care biologics market, by product

The global wound care biologics market is segmented into biological skin substitutes and topical agents based on product. Biological skin substitutes dominated the wound care biologics market in 2021. Factors contributing to the growth of this market segment include the increasing prevalence of target conditions such as ulcers and the rising geriatric population.

In 2021, ulcers segment accounted for the largest share in the market, by wound type

The wound care biologics market is segmented into ulcers, surgical & traumatic wounds, and burns by wound type. The ulcers segment accounted for the largest share of the wound care biologics market in 2021. Factors such as the increasing incidence of diabetes and growing geriatric patient population, the increasing prevalence of DFUs, and the growing incidence of venous leg ulcers are driving the growth of this segment. 

In 2021, hospitals segment accounted for the largest share in the market, by end user

The wound care biologics market is segmented into hospitals, ambulatory surgery centers, and burn care centers & wound clinics. In 2021, hospitals accounted for the largest share of the wound care biologics market. This can be attributed to the high demand for wound care biologic products in hospitals and the high patient inflow in this care setting.

In 2021, North America accounted for the largest share of the wound care biologics market

The global wound care biologics market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the wound care biologics market in 2021. Factors such as the increasing prevalence of chronic disorders, increasing healthcare spending, and the increasing demand for advanced wound treatment options like wound care biologics products are contributing to the large share of this regional segment.

Some of the prominent players in the Wound Care Biologics Market include:  Smith & Nephew plc (UK), Organogenesis Inc. (US), MIMEDX (US), Integra LifeSciences (US), Stryker Corporation (US), Mölnlycke Health Care AB (Sweden), Vericel Corporation (US), Bioventus LLC (US), Anika Therapeutics, Inc. (US), AbbVie Inc. (US), Kerecis (Iceland), Marine Polymer Technologies, Inc. (US), Merakris Therapeutics (US), PolyMedics Innovations GmbH (Germany), Fibroheal Woundcare Pvt. Ltd. (India), Anamay Biotech, Inc. (India), Virchow Biotech Private Limited (India), Medline Industries, LP (US), Tides Medical (US), Viscus Biologics LLC (US), Stability Biologics (US), MTF Biologics (US), Skye Biologics Holdings, LLC (US), AlloSource (US), and SurgiLogix (US)

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Wound Care Biologics market

By Product

• Biological Skin Substitutes
• Human Donor Tissue-derived Products
• Acellular Animal-derived Products
• Biosynthetic Products
• Topical Agents

By Wound Type

• Ulcers
• Diabetic Foot Ulcers
• Venous Ulcers
• Pressure Ulcers
• Other Ulcers
• Surgical & Traumatic Wounds
• Burns

By End User

• Hospitals
• Ambulatory Surgery Centers
• Burn Care Centers & Wound Clinics

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Wound Care Biologics Market Study:

• Growth of Wound Care Biologics in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Wound Care Biologics and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Wound Care Biologics Consumption Analysis
•  Wound Care Biologics Production Analysis
•  Wound Care Biologics and Management